Specialty pharmaceutical company Talphera Inc (Nasdaq: TLPH) announced on Tuesday that following a meeting with the US Food and Drug Administration (FDA), the agency has agreed to review a Prior Approval Supplement (PAS) requesting a reduction in the number of patents in the NEPHRO CRRT clinical study of Niyad, a lyophilized formulation of nafamostat.
A PAS is reviewed by the FDA within 30 days, and its approval by the agency is required before formally amending the study protocol.
During this same meeting, the agency agreed to two other changes to expand the clinical study inclusion criteria that will allow Talphera to enrol patients already on continuous renal replacement therapy (CRRT) beyond 48 hours and heparin-tolerant patients at certain institutions. These changes are being made through a five-day protocol amendment notice to the FDA with no additional FDA review needed.
Shakil Aslam, MD, Talphera's chief medical officer, said: "We continue to evaluate and focus on opportunities to support completion of the NEPHRO CRRT study by the end of the year. In addition to new clinical sites, our continuous improvement efforts in study execution were strengthened following our positive face-to-face meeting with the FDA where the agency agreed we should submit a PAS to reduce the number of patients in the NEPHRO CRRT study. We plan to submit the PAS in the coming week which requires a review period of up to 30 days. Our breakthrough designation status and close collaboration with the FDA continue to support our confidence in the importance of nafamostat as an alternative anticoagulant for patients on CRRT."
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review